Intelligence / Healthtech / PMA Approvals / Biotronik, INC.
Biotronik, INC.
25 Sept 2026: Device change approved (PMA) · Edora 8 HF-T QP 407137 Edora 8 HF-T 407138 Evity 8 HF-T QP 407139 Evity 8 HF-T 407140 Enitra 8 HF-T QP 407141 Enitra 8 H. Recorded in the openFDA device PMA data.
- Decided
- 25 Sept 2026
- Device
- Edora 8 HF-T QP 407137 Edora 8 HF-T 407138 Evity 8 HF-T QP 407139 Evity 8 HF-T 407140 Enitra 8 HF-T QP 407141 Enitra 8 H
- Specialty
- Cardiovascular
- Type
- Supplement (Normal 180 Day Track)
- Reason
- Change Design/Components/Specifications/Material
- Reference
- P070008 S172
- Location
- Lake Oswego, OR
A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.
- Cardiovascular leads with 53 of 120, then Pathology (15).
- 35 added in the 30 days to 18 Nov 2026.
Find the decision makers at Biotronik, INC.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Biotronik, INC. in our registers.
More in Cardiovascular
PMA Approvals
Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.